Quantcast

Latest Akesis Pharmaceuticals Inc. Stories

2008-11-06 06:00:21

Akesis Pharmaceuticals, Inc. (OTCBB:AKES) today announced it is broadening its business model to include the development of a wider range of specialty pharmaceuticals targeting metabolic diseases. As part of the new strategy the Company will look to in-license preclinical and clinical compounds in these disease settings. "This new strategic direction will provide more opportunities to build on the success of our AKP-020 program, a Type 2 diabetes drug candidate," said Carl LeBel, Ph.D.,...

2008-11-05 06:00:20

Akesis Pharmaceuticals, Inc. (OTCBB:AKES) today announced that current president and chief operating officer, Carl LeBel, Ph.D., has been appointed to the role of president and chief executive officer. Dr. LeBel has served as president and chief operating officer since June 2008 and has been on Akesis' board of directors since December 2007. The Company stated that current chairman and chief executive officer, Jay Lichter, Ph.D., will now assume the position of executive chairman of the board...

2008-09-22 06:00:30

Akesis Pharmaceuticals, Inc. (OTCBB:AKES), an emerging diabetes drug-development company, today announced the initiation of the next phase of the preclinical safety program for AKP-020. While an analysis of the one-month preclinical safety studies is ongoing, the company has initiated a three-month preclinical safety program in order to support further clinical evaluation of its product. Combined with the thorough analysis of the recent Phase IIa study of AKP-020 in diabetic subjects, the...

2008-07-18 12:01:14

Akesis Pharmaceuticals, Inc. (OTCBB: AKES), an emerging metabolic disease drug development company, today announced it has appointed Christos Mantzoros, MD, DSc, to its scientific advisory board (SAB). Dr. Mantzoros is an Associate Professor of Medicine at Harvard Medical School and an Associate Professor in Epidemiology at the Harvard School of Public Health. He serves as the Clinical Research Overseer of the Division of Endocrinology Diabetes and Metabolism at Beth Israel Deaconess Medical...

2008-06-30 09:03:37

Akesis Pharmaceuticals, Inc. (OTCBB:AKES), an emerging diabetes drug-development company, today announced it has named Carl LeBel, Ph.D., as president and chief operating officer. Dr. LeBel has served on Akesis' board of directors since December 2007. The company stated that current president, Jay Lichter, Ph.D., will retain the position of chief executive officer and add the title of chairman of the board of directors. "The current level of Company activity around our AKP-020 program for...

2008-06-24 09:03:24

Akesis Pharmaceuticals, Inc. (OTCBB:AKES), an emerging diabetes drug-development company, today announced it plans to begin a 13-week preclinical safety program for AKP-020, a novel vanadium compound that has shown considerable potential as a treatment for Type 2 diabetes. The studies will be conducted by Charles River Laboratories, and follows a recently completed 28-day preclinical safety program, also performed by Charles River. Earlier this month the company also announced positive...

2008-06-17 09:01:13

Akesis Pharmaceuticals, Inc. (OTCBB: AKES), an emerging diabetes drug-development company, today announced positive results of its preliminary analysis from its placebo-controlled Phase IIa trial designed to test the safety and efficacy of AKP-020, a novel vanadium compound, in patients with Type 2 diabetes. In this single blinded study seven type 2 diabetic subjects were dosed with AKP-020 and two with placebo for 28 days. Over the 28-day period, both placebo subjects showed an increase...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related